Alto Ingredients Beheer
Beheer criteriumcontroles 4/4
De CEO Alto Ingredients is Bryon McGregor, benoemd in Aug2023, heeft een ambtstermijn van 2.92 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.48M, bestaande uit 37.5% salaris en 62.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.24% van de aandelen van het bedrijf, ter waarde $ 4.76M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.9 jaar en 4.1 jaar.
Belangrijke informatie
Bryon McGregor
Algemeen directeur
US$1.5m
Totale compensatie
| Percentage CEO-salaris | 37.50% |
| Dienstverband CEO | 2.9yrs |
| Eigendom CEO | 1.2% |
| Management gemiddelde ambtstermijn | 2.9yrs |
| Gemiddelde ambtstermijn bestuur | 4.1yrs |
Recente managementupdates
Recent updates
Seeking Alpha • Jul 20
Alto Ingredients: Stop The Madness - This High Flyer Has 27% Downside
Summary Alto Ingredients is rated Sell due to overvaluation and heavy reliance on Section 45Z tax credits for profitability. Over half of ALTO’s operating income is driven by tax credits set to expire in 2029, introducing significant legislative risk. Core operating fundamentals remain weak, with modest 4% revenue growth and volatile ethanol crush margins driving earnings unpredictability. I assign a $4.30 price target, reflecting 26.3% downside, as current multiples are unjustified without sustainable margin or credit improvements. Read the full article on Seeking AlphaAnalyse-artikel • Jun 18
Alto Ingredients (ALTO) Stock Could Be 44.3% Undervalued After $8.9 Million 45Z Credit Sale
Alto Ingredients (ALTO) has drawn fresh attention after monetizing its 2025 Section 45Z Clean Fuel Production Tax Credits, securing about $8.9 million in cash that ties directly to its low-carbon ethanol operations. See our latest analysis for Alto Ingredients. That cash injection from Section 45Z tax credits lands at a time when Alto Ingredients’ share price has risen 88.53% year to date, with a 30 day share price return of 6.25% and a one year total shareholder return of 332.33%. These...
Narratiefupdate • Jun 18
ALTO: Stock Outlook Will Center On Future Clean Fuel Tax Credits
The analyst price target for Alto Ingredients has been revised from about $5.50 to roughly $10.00. Analysts attribute this change to updated assumptions on discount rates, profitability, and future P/E expectations.
Narratiefupdate • Jun 04
ALTO: Funded MASH Path And Liver Programs Are Expected To Drive Upside
Analysts have lifted the fair value estimate for Alto Ingredients to $9.00 from $6.75, reflecting updated assumptions around revenue growth, margins, and a lower projected P/E multiple informed by recent Street research on comparable clinical and funding setups. Analyst Commentary Recent Street research on peer companies in adjacent clinical and funding situations highlights how valuation work is being reshaped by dilution, funding visibility, and evolving program focus.
Narratiefupdate • May 15
ALTO: Future Returns Will Hinge On MASH Trials And Alcohol Liver Data
Alto Ingredients' analyst price target has been revised higher to $8.00 from $4.50, with analysts citing updated assumptions about the discount rate, revenue growth, profit margin, and future P/E to reflect recent research on the company's pipeline and market opportunities. Analyst Commentary While the revised US$8.00 price target reflects updated assumptions about Alto Ingredients' potential, some of the broader Street research on comparable stocks highlights why not all analysts are leaning in aggressively on valuation.Narratiefupdate • Apr 23
ALTO: MASH And Alcohol-Related Liver Programs Will Drive Future Upside Potential
Alto Ingredients' analyst fair value estimate has shifted from $4.00 to $6.75 as analysts factor in updated assumptions on discount rate, revenue growth, margins, and a higher future P/E in light of recent bullish coverage and revised price targets tied to pemvidutide's MASH and alcohol-related disease programs. Analyst Commentary Bullish Takeaways Bullish analysts are focused on pemvidutide as a differentiated asset for MASH and alcohol-related liver disease.Narratiefupdate • Apr 09
ALTO: Future Returns Will Depend On MASH Trials And Alcohol Liver Data
Analysts have raised Alto Ingredients' price target to $25 from $12, citing pemvidutide's potential in MASH and alcohol-related liver and use disorders as key factors behind the revision. Analyst Commentary Recent Street research on Alto Ingredients highlights a mixed backdrop, with optimistic views on pemvidutide and the MASH program set against more cautious assessments of risk and valuation.Narratiefupdate • Mar 26
ALTO: Future Returns Will Hinge On MASH Trials And Funding Discipline
Analysts have raised their average price target for Alto Ingredients to $25 from $12, citing a sharpened focus on the planned MASH pivotal program and added potential value from pemvidutide in alcohol use disorder and alcohol liver disease, along with a solid cash runway and upcoming clinical catalysts. Analyst Commentary Recent Street research on Altimmune reflects a mix of optimism around the clinical pipeline and caution around execution risks and valuation.Narratiefupdate • Mar 11
ALTO: Future Returns Will Depend On Execution And Funding Discipline
Analysts have raised their price target on Alto Ingredients to $4.50 from $3.00, citing updated assumptions around fair value, discount rate, expected revenue growth, profit margins, and future P/E that they say are more in line with recent Street research on comparable companies. Analyst Commentary While the higher price target reflects updated valuation work, some bearish analysts in the broader small cap space are still emphasizing execution and funding risks that can weigh on sentiment for companies like Alto Ingredients.Narratiefupdate • Feb 25
ALTO: Future Upside Will Depend On Delivering Consistent Margin Execution
Analysts have adjusted their price target on Alto Ingredients to $3.00, with the neutral fair value and updated assumptions on discount rate, revenue growth, profit margin, and future P/E reflecting a refined view of the company’s risk and earnings profile following recent supportive research coverage. Analyst Commentary Recent research on Alto Ingredients has focused on reassessing the balance between potential upside and the risks tied to execution, earnings quality, and market conditions.Narratiefupdate • Feb 11
ALTO: Fair Outlook Will Rely On Sustaining Margins And Execution
Analysts have raised their price target for Alto Ingredients to US$3.00, reflecting updated views that include modestly higher revenue growth, slightly stronger profit margins, a lower discount rate, and a revised future P/E assumption, supported in part by recent bullish Street research. Analyst Commentary While the updated US$3.00 price target points to a more constructive stance overall, some bearish analysts remain cautious and continue to flag risk around how Alto Ingredients can justify this valuation through execution and earnings delivery.Narratiefupdate • Jan 27
ALTO: Upcoming Liver Meeting Data Will Support Repriced Risk Reward Profile
Analysts recently trimmed their 12 month price target on Alto Ingredients by US$1 to US$14, citing refreshed assumptions around discount rates, revenue growth, profit margins, and future P/E multiples. Analyst Commentary Bearish analysts trimming price targets on comparable small cap names to around US$14, even when maintaining constructive ratings, suggest a tighter margin for error around assumptions such as discount rates, revenue growth, profit margins, and future P/E multiples.Narratiefupdate • Jan 12
ALTO: Upcoming Late-Stage Liver Data Will Support Repriced Risk Reward Profile
Narrative Update: Alto Ingredients Analyst Price Target Shift Analysts have trimmed their price target on Alto Ingredients by $1 to $14, citing updated risk and growth assumptions after the timing and outlook of recent clinical data were refined. Analyst Commentary Recent Street research reflects a more cautious tone, with bearish analysts trimming price targets and rechecking their assumptions on risk and potential upside.Narratiefupdate • Dec 26
ALTO: Upcoming Late-Stage Data Will Shape Risk Profile Amid Measured Outlook
Analysts have modestly lowered their price target on Alto Ingredients, trimming fair value by $1 to $14 as they factor in slightly softer long term assumptions, while remaining encouraged by upcoming late stage data presentations. Analyst Commentary Bearish analysts have pointed to the recent price target reduction to $14 as evidence that expectations for Alto Ingredients' long term growth and profitability are being tempered, even as upcoming late stage data remains a potential catalyst.Analyse-artikel • Dec 22
Alto Ingredients, Inc.'s (NASDAQ:ALTO) Shares Leap 41% Yet They're Still Not Telling The Full Story
Alto Ingredients, Inc. ( NASDAQ:ALTO ) shares have continued their recent momentum with a 41% gain in the last month...Narratiefupdate • Dec 12
ALTO: Lower Discount Rate Will Support Improved Risk Profile Ahead
Analysts have raised their price target on Alto Ingredients by about $0.50, citing a lower perceived risk profile driven by a reduced discount rate, stronger expected revenue growth, and a modest improvement in projected profit margins and future valuation multiples. Analyst Commentary Bearish analysts remain cautious on Alto Ingredients despite the recent upward revision to the price target, emphasizing that the new target still embeds a meaningful discount to peers on key growth and profitability metrics.Analyse-artikel • Nov 07
Alto Ingredients, Inc. (NASDAQ:ALTO) Shares Fly 28% But Investors Aren't Buying For Growth
Alto Ingredients, Inc. ( NASDAQ:ALTO ) shares have continued their recent momentum with a 28% gain in the last month...Analyse-artikel • Jul 04
Alto Ingredients, Inc. (NASDAQ:ALTO) Held Back By Insufficient Growth Even After Shares Climb 31%
Alto Ingredients, Inc. ( NASDAQ:ALTO ) shares have continued their recent momentum with a 31% gain in the last month...
Nieuw narratief • May 04
CO2 Plant Integration Will Boost Production And Exports
Acquisition and integration of the CO2 processing plant are expected to improve financials through cost synergies, increased capacity, and enhanced revenue streams.Analyse-artikel • Apr 22
Health Check: How Prudently Does Alto Ingredients (NASDAQ:ALTO) Use Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analyse-artikel • Nov 12
Alto Ingredients (NASDAQ:ALTO) Is Making Moderate Use Of Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analyse-artikel • Jul 17
Alto Ingredients, Inc.'s (NASDAQ:ALTO) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Alto Ingredients, Inc. ( NASDAQ:ALTO ) shareholders are no doubt pleased to see that the share price has bounced 26% in...Analyse-artikel • Jun 28
Would Alto Ingredients (NASDAQ:ALTO) Be Better Off With Less Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analyse-artikel • Jan 15
Here's Why Alto Ingredients (NASDAQ:ALTO) Can Afford Some Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Analyse-artikel • Dec 20
Alto Ingredients, Inc. (NASDAQ:ALTO) Surges 25% Yet Its Low P/S Is No Reason For Excitement
Those holding Alto Ingredients, Inc. ( NASDAQ:ALTO ) shares would be relieved that the share price has rebounded 25% in...Analyse-artikel • Sep 15
Is Alto Ingredients (NASDAQ:ALTO) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analyse-artikel • Apr 10
We Think Alto Ingredients (NASDAQ:ALTO) Has A Fair Chunk Of Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Analyse-artikel • Dec 16
Is Alto Ingredients (NASDAQ:ALTO) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$28m |
| Dec 31 2025 | US$1m | US$554k | US$12m |
| Sep 30 2025 | n/a | n/a | -US$51m |
| Jun 30 2025 | n/a | n/a | -US$68m |
| Mar 31 2025 | n/a | n/a | -US$60m |
| Dec 31 2024 | US$1m | US$537k | -US$60m |
| Sep 30 2024 | n/a | n/a | -US$37m |
| Jun 30 2024 | n/a | n/a | -US$39m |
| Mar 31 2024 | n/a | n/a | -US$28m |
| Dec 31 2023 | US$1m | US$427k | -US$29m |
| Sep 30 2023 | n/a | n/a | -US$43m |
| Jun 30 2023 | n/a | n/a | -US$68m |
| Mar 31 2023 | n/a | n/a | -US$53m |
| Dec 31 2022 | US$720k | US$352k | -US$43m |
| Sep 30 2022 | n/a | n/a | US$26m |
| Jun 30 2022 | n/a | n/a | US$51m |
| Mar 31 2022 | n/a | n/a | US$37m |
| Dec 31 2021 | US$910k | US$336k | US$44m |
| Sep 30 2021 | n/a | n/a | -US$12m |
| Jun 30 2021 | n/a | n/a | US$7m |
| Mar 31 2021 | n/a | n/a | US$13m |
| Dec 31 2020 | US$482k | US$331k | -US$16m |
| Sep 30 2020 | n/a | n/a | -US$37m |
| Jun 30 2020 | n/a | n/a | -US$80m |
| Mar 31 2020 | n/a | n/a | -US$102m |
| Dec 31 2019 | US$401k | US$318k | -US$90m |
Compensatie versus markt: De totale vergoeding ($USD 1.48M ) Bryon } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 2.43M ).
Compensatie versus inkomsten: De vergoeding van Bryon is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Bryon McGregor (62 yo)
2.9yrs
Tenure
US$1,477,220
Compensatie
Mr. Bryon T. McGregor served as Chief Financial Officer of Alto Ingredients, Inc. (formerly known as Pacific Ethanol, Inc.) (formerly Aventine Renewable Energy Holdings, Inc.) since November 19, 2009 until...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO, President & Director | 2.9yrs | US$1.48m | 1.24% $ 4.8m | |
| Chief Financial Officer | 2.9yrs | US$789.85k | 0.33% $ 1.3m | |
| Chief Operating Officer | 2.3yrs | US$771.96k | 0.24% $ 915.1k | |
| Chief Legal Officer & Secretary | 4.4yrs | US$772.28k | 0.30% $ 1.2m | |
| Chief Commercial Officer | no data | US$771.65k | 0.57% $ 2.2m | |
| Vice President of Human Resources | no data | geen gegevens | geen gegevens |
2.9yrs
Gemiddelde duur
53yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van ALTO wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.9 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO, President & Director | 2.1yrs | US$1.48m | 1.24% $ 4.8m | |
| Independent Director | 1.1yrs | US$84.28k | 0.078% $ 299.5k | |
| Independent Vice-Chair of the Board | 6.7yrs | US$146.20k | 0.31% $ 1.2m | |
| Independent Chairman of the Board | 6.7yrs | US$168.30k | 1.08% $ 4.2m | |
| Independent Director | 4.1yrs | US$146.20k | 0.23% $ 890.7k |
4.1yrs
Gemiddelde duur
62yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van ALTO wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.1 jaar).
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/07/24 15:13 |
| Aandelenkoers aan het einde van de dag | 2026/07/23 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Alto Ingredients, Inc. wordt gevolgd door 9 analisten. 2 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Carter Driscoll | B. Riley Securities, Inc. |
| Hamed Khorsand | BWS Financial Inc. |
| Eric Stine | Craig-Hallum Capital Group LLC |